A randomized, double-blind trial of women aged 18 to 55 years with acute uncomplicated cystitis compared ciprofloxacin (n = 150) with cefpodoxime (n = 150).4 Study subjects were randomized to receive either 250 mg of ciprofloxacin orally twice daily for 3 days or 100 mg of cefpodoxime proxetil orally twice daily for 3 days. The primary end point was overall clinical cure (defined as not requiring antimicrobial treatment during follow-up) at the 30-day follow-up visit.
The study demonstrated that the overall clinical cure rate at the 30-day visit with the intent-totreat approach in which patients lost to follow-up were considered as having clinical cure was 93% for ciprofloxacin compared with 82% for cefpodoxime (difference of 11%; 95% CI, 3%-18%). For the intent-to-treat approach, in which patients lost to follow-up were considered as having not responded to treatment, the clinical cure rate was 83% for ciprofloxacin compared with 71% for cefpodoxime (difference of 12%; 95% CI, 3%-21%).
The authors concluded that the use of cefpodoxime as a first-line fluoroquinolone-sparing antimicrobial for acute uncomplicated cystitis cannot be supported by this trial.
1. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394-1404.
2. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes [published online ahead of print March 26, 2012]. N Engl J Med. 2012;366(17):1567-1576.
3. Wegwarth O, Schwartz LM, Woloshin S, Gaissmaier W, Gigerenzer G. Do physicians understand cancer screening statistics? a national survey of primary care physicians in the United States. Ann Intern Med. 2012;156(5):340-349.
4. Avery AJ, Rodgers S, Cantrill JA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis [published online ahead of print February 21, 2012]. Lancet. 2012;379(9823):1310-1319.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs